Your browser is no longer supported. Please, upgrade your browser.
Settings
AXON Axovant Sciences Ltd. daily Stock Chart
AXON [NASD]
Axovant Sciences Ltd.
Index- P/E- EPS (ttm)-1.90 Insider Own73.20% Shs Outstand112.18M Perf Week21.05%
Market Cap283.82M Forward P/E- EPS next Y-1.49 Insider Trans139.21% Shs Float46.95M Perf Month21.05%
Income-204.20M PEG- EPS next Q-0.36 Inst Own10.90% Short Float9.62% Perf Quarter-1.56%
Sales- P/S- EPS this Y-13.10% Inst Trans-0.19% Short Ratio5.26 Perf Half Y125.89%
Book/sh0.24 P/B10.54 EPS next Y-4.90% ROA-114.90% Target Price4.70 Perf Year-59.58%
Cash/sh0.83 P/C3.06 EPS next 5Y- ROE-228.80% 52W Range1.02 - 6.59 Perf YTD-51.99%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.61% Beta0.14
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low148.04% ATR0.18
Employees45 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)63.07 Volatility10.30% 8.20%
OptionableYes Debt/Eq2.05 EPS Q/Q26.10% Profit Margin- Rel Volume1.70 Prev Close2.44
ShortableYes LT Debt/Eq1.48 EarningsNov 06 AMC Payout- Avg Volume858.83K Price2.53
Recom2.40 SMA2012.87% SMA5014.80% SMA20023.29% Volume1,456,993 Change3.69%
Jan-10-18Upgrade Chardan Capital Markets Sell → Neutral $2.50
Dec-21-17Downgrade Jefferies Buy → Hold
Sep-27-17Downgrade Robert W. Baird Outperform → Neutral $29 → $6
Sep-26-17Reiterated Chardan Capital Markets Sell $8 → $3
Sep-26-17Downgrade Piper Jaffray Overweight → Neutral
Sep-08-17Resumed Evercore ISI Outperform $30
Jul-11-17Initiated Jefferies Buy
Jun-14-17Reiterated Oppenheimer Outperform $26 → $30
Dec-20-16Initiated Laidlaw Sell $7.50
Dec-07-16Initiated Oppenheimer Outperform $20
Jun-07-16Initiated Leerink Partners Outperform $22
Jan-08-16Initiated H.C. Wainwright Buy $35
Oct-22-15Initiated Piper Jaffray Overweight
Sep-25-15Reiterated Chardan Capital Markets Sell $9.50 → $8
Jul-15-15Initiated JMP Securities Mkt Outperform $36
Jul-13-15Initiated Robert W. Baird Outperform $29
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Jul-06-15Initiated Jefferies Buy $31
Jun-18-15Initiated Chardan Capital Markets Sell $10
Oct-11-18 08:39AM  Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock? Zacks
Oct-09-18 09:02AM  Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy GlobeNewswire +7.84%
Sep-20-18 07:00AM  Axovant to Present at Two Upcoming Investor Conferences GlobeNewswire
Sep-17-18 09:00AM  Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases PR Newswire -6.31%
Aug-29-18 07:00AM  Axovant to Present at Upcoming Investor Conferences GlobeNewswire +8.04%
Aug-22-18 08:00AM  Today's Research Reports on Stocks to Watch: Axovant Sciences and Gevo ACCESSWIRE
Aug-07-18 07:03PM  Axovant: Fiscal 1Q Earnings Snapshot Associated Press
04:05PM  Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Jul-16-18 08:40AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks -7.87%
Jul-12-18 08:59AM  3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018 Zacks
Jul-11-18 09:41AM  Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More Zacks +6.05%
Jul-10-18 05:15PM  Axovant, Benitec Gain on Licensing Deal for Gene Therapy Zacks -6.06%
Jul-09-18 11:04AM  Axovant, Benetic Jump on Agreement to Develop Gene Therapy for MD TheStreet.com
Jul-08-18 08:18PM  Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma GlobeNewswire
Jun-26-18 10:39AM  Biotech startup Roivant cuts staff, forms two new subsidiaries American City Business Journals -9.73%
Jun-19-18 12:25PM  Here's Why Axovant Sciences Fell as Much as 21.3% Today Motley Fool -15.20%
Jun-18-18 08:30AM  Axovant to Present at First Annual Roivant Pipeline Day GlobeNewswire -9.76%
Jun-13-18 10:34AM  Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod Zacks
Jun-12-18 04:34PM  Why Xunlei, Griffon, and Axovant Sciences Slumped Today Motley Fool -18.16%
Jun-11-18 09:04AM  What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month InvestorPlace
08:50AM  Implied Volatility Surging for Axovant (AXON) Stock Options Zacks
08:44AM  Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher Zacks
Jun-09-18 11:32AM  Breakeven On The Horizon For Axovant Sciences Ltd (NASDAQ:AXON) Simply Wall St.
07:18AM  3 Drug Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-08-18 10:04AM  Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session Zacks
08:43AM  $842M gene therapy deal to boost development by Roivant spinoff in Durham American City Business Journals
07:20AM  Wired News Axovant Inked $842.5 Million Licensing Deal with Oxford BioMedica to Develop OXB-102 for Parkinsons Treatment ACCESSWIRE
Jun-07-18 05:08PM  Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica Zacks +5.49%
04:30PM  Why Camping World Holdings, Axovant Sciences, and Sonic Jumped Today Motley Fool
01:33PM  Oppenheimer: Axovant Deal Transform Pipeline Benzinga
12:10PM  Here's Why Axovant Sciences Stock Skyrocketed Today Motley Fool
10:30AM  These Stocks Are Leading the Nasdaq's Record-Setting Push TheStreet.com
08:00AM  Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics ACCESSWIRE
07:47AM  57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS ACCESSWIRE
Jun-06-18 12:53PM  Gene Therapy Deal Helps Double Price of Beaten-Down Biotech Company's Shares Bloomberg +160.00%
10:23AM  This Biotech Experiment is Paying Off The Wall Street Journal
07:29AM  UPDATE: Axovant shares soar 51% premarket on $842.5 mln licensing pact for Parkinson's treatment MarketWatch
02:00AM  Axovant Licenses Investigational Gene Therapy for Parkinsons Disease from Oxford BioMedica and Announces Key Leadership Team Addition GlobeNewswire
01:11AM  [$$] Oxford BioMedica seals $842m Parkinsons therapy deal with Axovant Financial Times
Jun-04-18 07:30AM  Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks ACCESSWIRE -9.38%
May-31-18 07:00AM  Axovant to Present at Two Upcoming Investor Conferences GlobeNewswire +16.55%
May-30-18 08:10AM  Todays Research Reports on Stocks to Watch: Axovant Sciences and Johnson & Johnson ACCESSWIRE
May-29-18 07:00AM  Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion GlobeNewswire +23.65%
Apr-26-18 01:31PM  Police Body Cameras Could Get Facial Recognition Technology Fortune
Mar-22-18 03:25PM  Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant Benzinga
Feb-15-18 08:30AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks
Feb-14-18 09:00AM  AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors Business Wire -9.94%
Feb-13-18 12:41AM  [$$] Axovant Stock Tumbles After Sweeping Leadership Changes The Wall Street Journal +17.92%
Feb-12-18 02:57PM  Axovant shares slide 21% premarket on news of CEO, COO departures MarketWatch -19.63%
01:54PM  [$$] Axovant Stock Tumbles After Sweeping Leadership Changes The Wall Street Journal
11:10AM  Axovant Sciences CEO David Hung resigns, shares tumble Reuters
10:18AM  Axovant Shares Crater as CEO and President Both Resign TheStreet.com
07:00AM  Axovant Sciences Announces Changes to Management Team and Board of Directors GlobeNewswire
Jan-17-18 06:10AM  Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18) TheStreet.com
Jan-10-18 11:45AM  After A Freefall In Axovant Shares, Chardan Upgrades Benzinga
08:46AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
07:23AM  Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-09-18 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
07:00AM  CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study GlobeNewswire
12:57AM  Despite Setbacks, Drugmakers Have Plans to Fight Alzheimers The Wall Street Journal
Jan-08-18 07:27PM  Drug Industry Isn't Giving Up on Alzheimer's The Wall Street Journal -56.98%
04:32PM  Why Dave & Buster's Entertainment, Axovant Sciences, and Five Below Slumped Today Motley Fool
12:35PM  Roivant-backed company partners with DCRI American City Business Journals
12:21PM  Here's Why Axovant Sciences Dropped Today Motley Fool
11:48AM  [$$] Axovant Will No Longer Develop Lead Dementia Drug The Wall Street Journal
10:10AM  Axovant Crumbles Following Alzheimers Study Update 24/7 Wall St.
10:03AM  Axovant shares plunge after key dementia drug programme scrapped Reuters
08:00AM  Axovant's stock tumbles toward record low after disappointing drug trial results MarketWatch
07:25AM  Axovant to scrap intepirdine program after dementia trial fails Reuters
07:00AM  Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study GlobeNewswire
Jan-05-18 07:00AM  Axovant to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-18 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Dec-19-17 08:53AM  Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock? Zacks
Dec-18-17 08:08AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Dec-15-17 08:08AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Dec-08-17 08:03AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit +5.58%
Nov-30-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-22-17 08:06AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-20-17 08:07AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit +7.82%
Nov-17-17 08:06AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-16-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-15-17 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Nov-06-17 11:22AM  Is Axovant Sciences Ltds (AXON) Balance Sheet A Threat To Its Future? Simply Wall St.
Nov-02-17 04:30PM  Axovant Announces Second Fiscal Quarter Financial Results and Corporate Updates GlobeNewswire
Oct-27-17 08:39AM  Alkermes (ALKS) in Focus: Stock Moves 11.1% Higher Zacks
Oct-25-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-24-17 08:03AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
07:30AM  [$$] Alector Nabs $205 Million in Development Deal With AbbVie The Wall Street Journal
Oct-20-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-18-17 08:42AM  Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher Zacks -6.07%
08:32AM  Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9% Zacks
Oct-17-17 08:39AM  uniQure (QURE) in Focus: Stock Moves 11.9% Higher Zacks
Oct-16-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-11-17 08:37AM  Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher Zacks
Oct-10-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
Oct-06-17 08:04AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit -10.98%
Oct-03-17 01:41PM  Roivant Wins A Battle Forbes
11:25AM  Biotech Can Keep Rallying Through The End Of The Year Barrons.com
09:53AM  After Intepirdine Flunked in Alzheimers Disease, Is Axovant Sciences a Buy? Motley Fool
Sep-30-17 12:31AM  [$$] How a Failed Alzheimers Drug Stung Some Large Hedge Funds The Wall Street Journal
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bickerstaff GeorgeDirectorAug 09Buy2.0725,00051,75050,000Aug 13 05:26 PM
SVF Investments (UK) Ltd10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:24 AM
VIKING GLOBAL INVESTORS LP10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:20 AM
VIKING GLOBAL PERFORMANCE LLC10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:21 AM
Lo Andrew10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:46 AM
Dexxon Holdings Ltd.10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:43 AM
QVT Associates GP LLC10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:38 AM
Machado Patrick10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 07:32 AM
Roivant Sciences Ltd.10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 07:31 AM
Modig BerndtDirectorDec 29Option Exercise0.9077,91470,12377,914Jan 03 08:39 AM